Drug patent expiry in 2021: Opportunities and challenges in the Korean market
Min Son of Hanol IP & Law looks ahead at the key deadlines in the South Korean drug patent market for 2021 Sponsored by January 12 2021
With each new year, pharmaceutical companies are faced with the loss of exclusivity that accompanies the expiration of their patents, and by the same token, drug manufacturers are also afforded new opportunities and challenges due to the entry of generic competition. In South Korea, as many as 62 patents for 158 pharmaceutical products are supposed to expire this year, with more than half of these expected to potentially be launched as generics in the absence of any additional patents in the patent listing.